Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q1 FY2026 Earnings Presentation
20 slides from Gland Pharma's earnings presentation, Aug 5, 2025
Slide 1: Exchange filing cover letter for Q1FY26 investor presentation
GLAND GLAND PHARMA LIMITED August 05, 2025 August 05, 2025 BSE Limited BSE Limited National National Stock Stock Exchange Exchange of of India India Limited Limited Corporate Relationship Corporate Relationship Department Department Listing Department Listing Department Phiroze Jeejeebhoy Phiroze Je
Slide 2: Investor Presentation Q1FY26
GLANDI GLAND PHARMA Investor Presentation Presentation Q1FY26 Q1FY26 05 August 2025
Slide 3: Safe Harbour Statement
Safe Safe Harbour Harbour Statement Statement The The Presentation Presentation is is to to provide provide the the general general background background information information about about the the Company’s activities Company’s activities as as at at the the date date of of the the Presentation. Pr
Slide 4: Financial Highlights
GLAND Financial Highlights Financial Highlights
Slide 5: Consolidated P&L Highlights
Consolidated Consolidated P&L P&L Highlights Highlights ₹ZMn Mn Particulars Particulars Q1 FY26 Q1 FY25 Q1 FY25 YoY Q4 FY25 QoQ QoQ Revenue Revenue from operations from operations 15,056 15,056 14,017 7% 14,249 14,249 6% 6% Other Income 575 575 514 12% 440 440 31% 31% Total Income Total Income 15,63
Slide 6: Consolidated Financial Highlights
Consolidated Consolidated Financial Financial Highlights Highlights Revenue Revenue from from Operations Operations Gross Gross Profit *1> / Gross Profit (1) Gross Profit Profit Margin (2) Margin & (₹ Mn) (< (₹ Mn / %) (< 14,249 15,056 14,017 9,845 9,370 8,375 60% 66% 65% Q1 FY25 Q4 FY25 Q1 FY26 Q1
Slide 7: Base Business (Gland) P&L Highlights
Base Base Business (Gland) P&L Business (Gland) P&L Highlights Highlights ₹ Mn Mn Particulars Q1 FY26 Q1 FY25 YoY Q4 FY25 QoQ Revenue from operations Revenue from operations 10,409 10,409 10,134 3% 3% 10,332 1% 1% Other Income 556 556 493 493 13% 13% 436 436 28% 28% Total Total Income Income 10,965
Slide 8: Base Business (Gland) Financial Highlights
Base Base Business (Gland) Financial Business (Gland) Financial Highlights Highlights Revenue Revenue from from Operations Operations Gross Gross Profit Gross Profit Profit (1) / Gross Profit Margin (2) Margin & (₹ (? Mn) Mn) (₹ Mn / %) (< 10,134 10,134 10,332 10,332 10,409 10,409 6,280 6,144 5,348
Slide 9: Group Financial Highlights (1/2)
Group Group Financial Financial Highlights Highlights (1/2) (1/2) (1) Net Net Worth Worth <1 > ROCE (2) ROCE (2) RONW (3) // RONW (3 > (₹ Mn) (? (%) (%) RoCE RoNW 87,238 95,587 91,507 11% 15.00% 11% 9% 10.00% 9% 9% 8% 5.00% 0.00% FY24 FY25 Jun'25 FY24 FY25 Jun'25 Capital Capital Expenditure Expendit
Slide 10: Group Financial Highlights (2/2)
Group Group Financial Financial Highlights Highlights (2/2) (2/2) Cash Cash and and Bank Bank Balances Balances // Net Cash (1) Net Cash Cash Cash Flow from Operations Flow from Operations (₹ Mn) ■■Total Total Cash Cash (₹ (? Mn) (? Net Cash Cash 4,277 25,562 26,179 3,259 22,870 23,009 2,620 18,394
Slide 11: Business Update
GLAND Business Update Business Update
Slide 12: Base Business (Gland) Updates
Base Business Base Business (Gland) (Gland) Updates Updates • R&D Expenses: Total Total R&D expenses were ?460 ₹460 million in Q1 FY26, representing 4.4% of revenue. • New Launches: The company launched 12 new molecules in regulated markets, including Colistimethate, Epinephrine, Vancomycin (three (
Slide 13: Cenexi Updates
Cenexi Updates Cenexi Updates Q1 FY26 Q1 FY26 Q1 FY25 Q1 FY25 Q4 FY25 Q4 FY25 Particulars Particulars YoY YoY QoQ QoQ € € Mn. Mn. ₹ Mn. ?Mn. € € Mn. Mn. ₹ Mn. ?Mn. € € Mn. Mn. ₹ Mn. ?Mn. Revenue from operations 48 4,648 43 3,883 20% 43 3,917 19% Gross Margin 38 38 3,701 3,701 34 3,026 3,026 22% 34 3
Slide 14: Geographical Revenue
GLAND Geographical Geographical Revenue
Slide 15: US Market
US US Market Market ?₹ Mn Mn Group Group Revenue Revenue Contribution Contribution Gland Gland Cenexi Cenexi -2% YoY -5% YoY 163% YoY 7,524 7,714 7,170 7,628 7,918 7,443 273 204 104 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 US US Filings Filings Update Update US US Cont
Slide 16: Europe Market
Europe Europe Market Market ₹ Mn ?Mn Group Revenue Contribution Gland Cenexi 29% YoY 57% YoY 23% 23% YoY YoY 639 3,302 2,663 2,801 2,399 2,566 407 402 2,159 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Europe Contribution to the Group Business Update •• Gland: Gland: Launc
Slide 17: Other Core Markets (Canada, Australia and New Zealand)
Other Other Core COPG Markets Markots (Canada, (Canada, Australia Australia and and New Zealand) New Zealand) ?₹ Mn Mn Group Revenue Contribution Gland Cenexi 65% YoY 144% YoY 5% YoY 739 437 473 601 253 266 447 164 194 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Other Oth
Slide 18: Rest of the World
Rest of the Rest of the World World ₹ Mn ZMn Group Revenue Contribution Gland Cenexi 5% YoY 3% YoY 6% YoY 1,481 1,533 2,849 2,978 1,254 2,404 1,368 1,445 1,150 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 RoW Contribution to the Group Business Update • Q1FY26 revenue incre
Slide 19: India
India India ₹ Mn ?Mn Gland India India Contribution Contribution to to the the Group Group Business Update 13% 13% YoY YoY 4% • Q1FY26 revenue increased by 13% over 594 Q1FY25, Q1FY25, driven by volume driven by volume growth in growth in 527 525 FY25 existing products, including Huminsulin. Q1 FY25
Slide 20: Thank You
iGiANPl GLAND PHARMA Thank You Thank You Corporate Office Investor Relations: Gland Gland Pharma Pharma Limited Limited Sampath Sampath Kumar Kumar Pallerlamudi Pallerlamudi Plot Plot No. No. 11 11 & & 84, 84, TSIIC TSIIC Phase: Phase: IV IV Company Company Secretary Secretary & & Compliance Complia